The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...
News Medical on MSN
Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors
Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.
Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...
In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...
Please provide your email address to receive an email when new articles are posted on . More than 7% of patients receiving immune checkpoint blockade therapy and antibiotics developed immune-related ...
Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed a novel cancer immunotherapy strategy that forces tumors to expose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results